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Abstract 
 
The management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the 
last decade. A number of different systemic molecular targeted agents that have been 
recently approved have improved the survival of patients with mRCC. This mini-review 
focuses on the implementation of multi-modality therapy in the management of mRCC and 
the approved indications of the various available novel agents. These novel agents have 
expanded our armamentarium and improved clinical outcomes of this challenging disease 
that has considerable biological heterogeneity and clinical variability.  Copyright: The Authors. 
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Introduction 
 
Kidney cancer is the twelfth most common 
cancer worldwide - 338,000 new cases were 
diagnosed in 2012 (1). The highest 
incidence of kidney cancer is seen in 
Northern America and Europe while the 
lowest incidence is seen in Africa and Asia. 
Of these, renal cell carcinoma (RCC) 
accounts for more than 90% of cases and 
represents about 2-3% of adult 
malignancies. Despite recent scientific 
advances in diagnosis and management 
almost 25-30% RCC patients are 
metastatic at diagnosis (2), and another 20-
30% of patients with localized disease who 
undergo nephrectomy develop metastasis, 
with a median time to relapse of 15-18 
months (3). 
 
Prognostic models 
 
There is considerable variability in the 
natural history of this disease and several 
prognostic models have been developed for 
metastatic RCC (mRCC). These models help 
clinicians while counselling patients 
regarding the expected clinical course and 
facilitate treatment planning. 
 
The most well-known of these is the 
MSKCC (Memorial Sloan-Kettering Cancer 
Center) model which has undergone several 
revisions across the years. The original 
publication established five prognostic 
factors to predict survival in patients with 
mRCC (4).  These included poor 
performance status (Karnofsky score <80), 
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elevated serum lactate dehydrogenase 
(LDH) level (>1.5 times upper limit of 
normal), low hemoglobin (less than the 
lower limit of normal), elevated corrected 
calcium concentration (>10 g/dL), and lack 
of prior nephrectomy. The overall survival 
(OS) in patients with no adverse factors 
(favorable-risk group), one to two risk 
factors (intermediate-risk group), and more 
than three risk factors (poor-risk group) 
were 20 months, 10 months, and 4 
months, respectively. Subsequent review in 
the interferon (IFN) alpha treated patients 
identified time from initial RCC diagnosis to 
start of IFN therapy of less than one year 
as another indicator of poor prognosis (5). 
 
The MSKCC model was externally validated 
by the Cleveland Clinic, who additionally 
identified prior radiotherapy and presence 
of hepatic, lung, and retroperitoneal nodal 
metastases to be predictors of poor 
prognosis (6). In the era of vascular 
endothelial growth factor (VEGF) targeted 
therapy, another prognostic model was 
derived from patients treated with the 
tyrosine kinase inhibitors (TKIs)  sorafenib, 
Sunitinib, and bevacizumab with IFN (7). 
This model is known as the Heng’s model 
or the International Metastatic RCC 
Database Consortium model. It includes 
six prognostic factors - hemoglobin less 
than the lower limit of normal, corrected 
calcium greater than the upper limit of 
normal (ULN), Karnofsky performance 
status less than 80%, time from diagnosis 
to treatment of less than one year, 
neutrophils greater than the ULN and 
platelets greater than the ULN. This model 
too has been externally validated in 
another dataset and has significant current 
utility in stratifying patients of ongoing 
clinical trials and clinical relevance while 
prognosticating patients (8). 
 
Role of surgery 
 
Surgery as an independent therapeutic 
modality has limited utility in the mRCC 
setting. However, cytoreductive 
nephrectomy followed by systemic therapy 
is still a recommended strategy for patients 
with resectable disease. The evidence for 
this strategy stems from two large 
randomized phase III trials where patients 
who underwent cytoreductive nephrectomy 
followed by IFN showed a survival benefit 
as compared to those who received IFN 
treatment alone (13.6 months versus 7.8 
months; p=0.002) (9).  The role of 
cytoreductive nephrectomy in the 
molecular therapy era is being studied in a 
number of prospective clinical trials, both 
as an upfront treatment strategy (10) or 
after neoadjuvant molecular targeted 
therapy (11). A retrospective analysis 
showed that patients who underwent 
cytoreductive nephrectomy followed by 
targeted therapy had prolonged survival as 
compared to those who received targeted 
therapy alone (20.6 months versus 9.5 
months; p<0.0001). The benefit was 
incremental as survival time lengthened, 
but for those with a survival of less than 
one year the benefit was marginal (12). 
Appropriate patient selection is therefore 
crucial and patient co-morbidities, disease-
related and prognostic factors, risks and 
benefits of surgery are all variables that 
have to be considered when planning 
cytoreductive nephrectomy. 
 
There also appears to be a role of 
metastatectomy in a proportion of mRCC 
patients with limited sites of metastasis 
amenable to complete resection, prolonged 
period of disease-free interval and good 
performance status (13). Observational 
data suggests that, for the carefully 
selected patient, aggressive surgical 
resection followed by systemic therapy has 
the potential to prolong 5-year overall 
survival to 20-30% (14).  Cytoreductive 
nephrectomy with palliative intent can also 
be offered to patients to control severe local 
or systemic symptoms such as intractable 
pain, bleeding and paraneoplastic 
manifestations such as hypercalcemia, 
hypertension, etc. 
 
Role of Radiation Therapy 
 
RCC is considered to be an inherently 
radio-resistant tumour and, in mRCC, 
radiation therapy is primarily used for 
palliation of sites of painful metastasis 
(especially bone) and for treatment of brain 
metastases. Technological advancements in 
the field of radiation oncology which 
include image-guided radiotherapy and 
stereotactic radiosurgery are being explored 
in this setting and may expand the role of 
radiation therapy in the future. 
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Systemic Therapy 
 
There are a number of agents that are now 
approved for systemic therapy in mRCC. 
These include cytokine therapy, 
immunotherapy, chemotherapy and 
molecular targeted therapy. The molecular 
targeted agents include VEGF inhibitors 
like bevacizumab, TKIs such as sorafenib, 
sunitinib and axitinib, and the mammalian 
target of rapamycin (mTOR) inhibitors 
temsirolimus and everolimus. Prior to the 
FDA approval of the first TKI sorafenib in 
December 2005, cytokine therapy was most 
frequently used for mRCC.  However due to 
the favorable side effect profile of the newer 
molecular targeted agents and their ease of 
administration, cytokine therapy usage has 
gradually decreased. 
 
Role of Cytokine Therapy and 
Immunotherapy 
 
RCC is an immunologically driven 
malignancy and has therefore been 
amenable to immune manipulation. A 
number of immune potentiating strategies 
have been explored but only a few of them 
have been clinically successful. The two 
agents that have been heavily investigated 
are IFN alpha and interleukin-2 (IL-2). 
These two still have a role in the first line 
therapy of clear cell mRCC. High dose IL-2 
is the only therapy that can produce 
durable complete or partial responses (14-
28%) in a small subset of patients with 
metastatic, relapsed or unresectable RCC 
(15,16).  Patient selection is critical as high 
dose IL-2 is associated with substantial 
toxicity and only patients with clear cell 
histology, an excellent performance status 
and minimal co-morbidity are likely to 
withstand this costly therapy and obtain 
benefit from it (17). 
 
IFN alpha as a single agent has a response 
rate up to 15%, however the duration of 
response is usually short lived at 
approximately 4 months (18). More 
recently, it has been investigated in 
combination with molecular targeted 
agents with mixed results and increased 
toxicity. One successful combination that 
is now approved for first line treatment of 
clear cell mRCC is IFN alpha with 
bevacizumab. 
 
Role of Targeted Therapy 
 
Several genetic and epigenetic changes are 
involved in the pathogenesis of RCC. 
Mutations in the von-Hippel-Landau (VHL) 
gene were first identified in hereditary RCC 
and then were also noted in 60-80% of 
sporadic RCC. The VHL protein is a tumor 
suppressor and this complex targets the 
hypoxia inducible factor (HIF) transcription 
factors which regulate important 
downstream targets such as VEGF, 
platelet-derived growth factor, and glucose 
transporter-1. However, a mutated VHL 
gene results in HIF accumulation and leads 
to a massive stimulation of growth factors 
which promote tumor growth and 
proliferation (19), including VEGF (20). The 
VEGF family ligands act via the VEGF 
receptor (VEGFR) to promote cell growth, 
proliferation, migration, chemotaxis and 
increase vascular permeability. This has a 
central role in cancer angiogenesis. VEGF 
inhibition was therefore investigated as a 
therapeutic strategy and initiated the 
development of several molecules, which 
ushered in the era of targeted therapy. Also 
involved in RCC pathogenesis is the mTOR 
pathway. The activation of mTOR complex 
results from the phosphatidylinositol 3-
kinase (PI3K) pathway by growth factor 
receptors and further leads to downstream 
signal transduction responsible for the 
regulation of cell growth, proliferation, 
apoptosis, and metabolism of the cell. This 
pathway has also lent itself to therapeutic 
application in the mRCC patient and other 
solid malignancies. 
 
Although it is simplistic to assume that the 
complex molecular cell signaling pathways 
can be permanently affected by a single 
molecule, the success of these targeted 
agents is proof of principle that at least 
temporarily the cancer cell can be 
effectively controlled. 
 
VEGF Inhibitors and TKIs 
 
Bevacizumab is currently the only 
intravenous VEGF inhibitor in clinical use 
against RCC. It is a recombinant 
humanized monoclonal immunoglobulin 
G1 monoclonal antibody (mAb) that binds 
to VEGF extracellularly and prevents 
binding of VEGF to the VEGFR (primarily 
VEGFR-2), which leads to inhibition of its 
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biologic activity. In the AVOREN study, 
bevacizumab in conjunction with IFN alpha 
as first line therapy for mRCC with clear 
cell histology prolongs median progression 
free survival (PFS) as compared to IFN 
alone (10.2 months versus 5.4 months; 
p=0.001), although there was no difference 
in OS (21,22). More than half the patients 
in both arms received at least one other 
line of therapy subsequently and this may 
have impacted the results of the OS 
analysis.  In the Cancer and Leukemia 
Group B (CALGB) 90206 trial (23), the 
combination of bevacizumab and IFN alpha 
prolonged PFS but not OS as compared to 
IFN alpha alone. Bevacizumab is therefore 
approved in combination with IFN alpha for 
the first line therapy of clear cell mRCC. It 
has also been investigated as combination 
therapy with a TKI or mTOR inhibitor. 
However, as this led to increased toxicity 
without significant improvement in efficacy 
(24), this is currently not a favored 
approach. 
 
Sunitinib is an oral multi-targeted TKI that 
binds to the intra-cellular domain of 
VEGFR, PDGF receptors (PDGFR) a and b, 
FLT-3, and other c-kit receptor tyrosine 
kinases. For treatment naïve patients with 
clear cell mRCC, sunitinib as compared to 
IFN alpha prolonged PFS (11 months 
versus 5 months; p =<0.001) (25) with 
higher overall response rate (ORR) in the 
sunitinib arm (31% versus 6%; p<.001). 
Sunitinib also resulted in prolonged OS 
(26.4 months versus 21.8 months; 
p=0.051), and patients on sunitinib had 
better quality of life (p= <0.0001). 
 
Pazopanib is also a multi-targeted TKI of 
VEGFR, PDGFR-a/b, and c-kit. It was 
investigated for both treatment naïve and 
post-cytokine therapy clear cell mRCC. In 
comparison with placebo, it improved PFS 
(9 months versus 4.2 months; p=0.0001) 
(26).  Both sunitinib and pazopanib are 
approved for first line treatment of mRCC, 
and the choice of therapy is often based on 
patient co-morbidities and keeping in 
consideration the side effect profile of these 
two drugs. The most severe adverse effects 
noted with sunitinib are neutropenia, 
thrombocytopenia, hyperamylasemia, 
diarrhea, hand-foot syndrome and 
hypertension. The side effects noted with 
pazopanib are diarrhea, hypertension, hair 
color changes, nausea, vomiting, anorexia, 
weakness, fatigue, hepatotoxicity, 
abdominal pain and headache. A large 
phase III non-inferiority trial with more 
than a thousand patients has 
demonstrated that the two drugs have 
similar efficacy. Pazopanib was found to be 
non-inferior to sunitinib with similar PFS 
and OS (27).  Pazopanib has demonstrated 
greater patient acceptability as compared 
to sunitinib in a cross over trial where 
patients were exposed to both drugs after 
suitable wash-out period of each drug (28). 
Pazopanib was superior to sunitinib in 
health related quality of life measures 
evaluating fatigue, hand, foot and mouth 
soreness. 
 
Sorafenib has a mechanism of action 
similar to sunitinib and, in addition to 
inhibiting VEGFR, FLT-3, c-kit, RET, 
PDGFR a and b, also inhibits serine and 
threonine and ras kinases. It was the first 
TKI approved for mRCC when it was shown 
to have an increase in response rate, 
prolongation of PFS and improvement in 
quality of life as compared to IFN alpha 
(29,30). At present, however, it is not 
routinely used in the first line setting, since 
the subsequent TKIs that were developed 
have demonstrated greater efficacy. 
 
Axitinib is an extremely potent second 
generation TKI that selectively targets 
VEGFR and to a lesser degree PDGFRs and 
c-kit. For patients who have failed a prior 
systemic therapy, axitinib as compared to 
sorafenib has shown an improved response 
rate and PFS (6.7 months versus 4.7 
months; p< 0.0001) (31). The benefit was 
more striking in patients who had received 
prior cytokine therapy. Outcome to second-
line therapy was better when duration of 
first-line treatment was longer (32). 
 
mTOR Inhibitors 
 
Temsirolimus administered intravenously 
was compared to IFN-alpha in a large 
multicenter phase III study of treatment 
naïve mRCC with poor prognosis (at least 3 
of 6 poor risk predictors) and all histologies 
(33). Patients in the temsirolimus alone 
arm had longer OS (10.9 months versus 
7.3 months; p = 0.008) and PFS (5.5 
months versus 3.1 months; p<0.001) than 
those on IFN. It is important to reiterate 
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that temsirolimus is the only drug that has 
approval for use in non-clear cell histology 
and poor prognosis mRCC. 
 
Everolimus is approved in the second line 
setting for patients who have progressed 
after TKI/VEGF inhibitor therapy. In a 
randomized phase III trial, patients with 
mRCC who had progressed on sunitinib, 
sorafenib or both, or previous 
bevacizumab, IFN and IL-2, were assigned 
to everolimus or placebo (34).  Median PFS 
was significantly longer in the everolimus 
arm as compared to the placebo arm (4.9 
months versus 1.9 months, p= < 0.0001). 
 
Although targeted therapy has changed our 
approach in treating patients with RCC, the 
evolution of the disease is such that these 
drugs cease to be effective after a limited 
period of time. Current studies are 
therefore evaluating combination regimens 
of targeted therapy with cytokine therapy 
or targeted therapies with different 
downstream signaling targets so as to 
prevent resistance and improve outcomes. 
This has not proven to be a very successful 
effort as the combinations studied have led 
to markedly increased toxicities without 
improving efficacy (35-40). 
 
Role of Chemotherapy 
 
Chemotherapy has a very limited role in 
clear cell RCC, however there is some 
evidence for its use in the sarcomatoid 
variant which carries a very poor prognosis 
(41). Gemcitabine and doxorubicin 
combination has shown up to 16% 
response rates, 26% stable disease rate 
with a median OS of 8.8 months and PFS 
of 3.5 months (42).  Gemcitabine has also 
been combined with capecitabine for 
metastatic progressive RCC with a 
response rate of 8.4 to 11% and median OS 
of 14.5 to 17.9 months (43-45). 
 
There is also some literature supporting the 
use of combination chemotherapy in non-
clear cell histologies especially for the renal 
medullary carcinoma and collecting duct 
carcinoma subtypes, both of which usually 
have advanced disease at presentation and, 
thereby, limited survival. Collecting duct 
carcinoma has histology similar to that of 
urothelial carcinoma, and gemcitabine 
combined with a platinum agent has 
shown response rates up to 26% with 
median PFS of 7.1 months and median OS 
of 10.5 months (46). Similar regimens have 
also been used in renal medullary 
carcinoma (47). 
 
Bone metastasis and supportive care 
 
Supportive therapy, including pain relief 
and efforts to improve quality of life should 
be offered to all patients with metastatic 
RCC, as despite all advances it remains a 
terminal disease. Bone is one of the most 
frequent sites of metastasis, and can lead 
to significant skeletal related morbidity 
which includes bone pain, pathological 
fractures, spinal cord compression and 
hypercalcemia secondary to malignancy. 
Zoledronic acid significantly reduces the 
risk of these skeletal related events by 
approximately 61% and the therapeutic 
interventions for these events that may 
include palliative radiation and surgery 
(48). It also is believed to have antitumour 
activity and can potentiate the anti-cancer 
effects of targeted therapy thereby 
prolonging tumor control (49). 
 
Denosumab is a fully human monoclonal 
antibody that binds to and neutralizes 
RANKL (receptor activator of nuclear factor-
κB ligand), inhibits osteoclast function and 
prevents generalized bone resorption and 
local bone destruction. It is non-inferior 
(trending to superiority) to zoledronic acid 
in preventing or delaying first on-study 
skeletal-related events in various 
malignancies, including mRCC (50). It is 
easy to administer since it is given by the 
subcutaneous route and the absence of 
significant renal toxicity makes it a 
particularly attractive novel therapeutic 
option for patients with mRCC. The 
majority of these patients has undergone a 
nephrectomy in the past and may have 
compromised renal function. 
 
Conclusion 
 
Multimodal, multi-disciplinary therapy is 
vital in the management mRCC, which 
remains a challenging and ultimately 
terminal disease. The management of this 
disease has continuously evolved through 
the years as increased scientific 
understanding of the molecular pathways 
involved in tumourigenesis led to 
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development of various new drugs that 
target these distinct pathways. The 
dilemma that physicians face currently and 
questions that need to be answered on an 
urgent basis are appropriate selection and 
sequencing of the various novel agents, 
optimal dosing and combination strategies 
for improving efficacy and enhancing 
clinical outcomes. 
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